156928-10-8Relevant articles and documents
Preparation method of hexahydrofuranofuranol derivative, intermediate and preparation method thereof
-
Paragraph 0082-0083; 0086; 0092-0093; 0096, (2021/02/05)
The invention relates to the field of medicine synthesis, in particular to a preparation method of a hexahydrofuranofuranol derivative, an intermediate and a preparation method thereof. The preparation method comprises a condensation reaction, a deprotection reaction and a cyclization reaction, wherein R1 and R2 are hydrogen or hydroxyl protecting groups, R3 is alkyl, acyl, ether, ester or aryl, and X is oxygen, sulfur or nitrogen. In the preparation process of the hexahydrofuranofuranol derivative, the compound shown in the formula I is subjected to a condensation reaction, so that the product with very high optical purity can be prepared by adopting the way. The preparation method can be used for commercially producing and preparing the darunavir key intermediate (3R, 3aS, 6aR)- hexahydrofuro-[2, 3-b]-3-ol, and is a very economical route suitable for industrial production.
Synthesis of hexahydro furo [2, 3 - b] furan - 3 - ol and its enantiomer
-
, (2017/08/03)
The invention discloses synthetic methods of hexahydrofuro[2,3-b]furan-3-ol and an enantiomer thereof. The synthetic method of hexahydrofuro[2,3-b]furan-3-ol comprises the step c or the step b to the step c or the step a to the step c in the following synthetic route as shown in the description. The synthetic method of the enantiomer (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-ol comprises the step c to the step f or the step b to the step f or the step a to the step f in the following synthetic route as shown in the description, wherein R1 is selected from C1 to C4 alkyl or aralkyl, and R2 is selected from C1 to C4 alkyl. The synthetic methods provided by the invention have the advantages of cheap and easily available raw materials, simple operation, low cost and the like, are suitable for large-scale production, and have practical value for realization of industrialized production of darunavir.
Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors
Ghosh, Arun K.,Xu, Chun-Xiao,Rao, Kalapala Venkateswara,Baldridge, Abigail,Agniswamy, Johnson,Wang, Yuan-Fang,Weber, Irene T.,Aoki, Manabu,Miguel, Salcedo Gomez Pedro,Amano, Masayuki,Mitsuya, Hiroaki
scheme or table, p. 1850 - 1854 (2011/06/22)
A healthier HAART: We report the design, synthesis, biological evaluation, and X-ray crystallographic analysis of a new class of HIV-1 protease inhibitors. Compound 4 proved to be an extremely potent inhibitor toward various multidrug-resistant HIV-1 variants, representing a near 10-fold improvement over darunavir (DRV). Compound 4 also blocked protease dimerization with at least 10-fold greater potency than DRV.